Oncotarget

Clinical Research Papers:

Prognosis of subtypes of the mucinous breast carcinoma in Chinese women: a population-based study of 32-year experience (1983-2014)

Bo Pan, Ru Yao, Jie Shi, Qian-Qian Xu, Yi-Dong Zhou, Feng Mao, Yan Lin, Jing-Hong Guan, Xue-Jing Wang, Yan-Na Zhang, Xiao-Hui Zhang, Song-Jie Shen, Ying Zhong, Ya-Li Xu, Qing-Li Zhu, Zhi-Yong Liang and Qiang Sun _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:38864-38875. https://doi.org/10.18632/oncotarget.8778

Metrics: PDF 1830 views  |   HTML 3748 views  |   ?  


Abstract

Bo Pan1,*, Ru Yao1,*, Jie Shi2,*, Qian-Qian Xu1, Yi-Dong Zhou1, Feng Mao1, Yan Lin1, Jing-Hong Guan1, Xue-Jing Wang1, Yan-Na Zhang1, Xiao-Hui Zhang1, Song-Jie Shen1, Ying Zhong1, Ya-Li Xu1, Qing-Li Zhu3, Zhi-Yong Liang2 and Qiang Sun1

1 Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China

2 Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China

3 Department of Ultrasound, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China

* These authors have contributed equally to this work

Correspondence to:

Qiang Sun, email:

Keywords: mucinous breast cancer, subtype, prognosis

Received: February 21, 2016 Accepted: April 04, 2016 Published: April 18, 2016

Abstract

Purpose: The heterogeneous nature of the mucinous breast cancer (MBC), with its pure (PMBC) and mixed subtypes (MMBC), calls for precise prognosis assessment.

Methods: We analyzed 197 consecutive MBC patients, including 117 PMBC and 80 MMBC, who were treated from 1983 to 2014. The clinicopathological features, treatment choice, disease-free survival (DFS) and overall survival (OS) were compared among PMBC, MMBC and MMBC subgroups. Prognostic factors of PMBC and MMBC were identified.

Results: Compared to PMBC, MMBC had more lymph node metastasis (p = 0.043), Her2 positivity (p = 0.036), high Ki-67 index (defined as>20%, p = 0.026) and anti-Her2 targeted therapy (p = 0.016). The 5-year DFS of PMBC and MMBC were 90.4% and 86.2%, whereas the 5-year OS were 99.0% and 98.7%. No significant difference was found in DFS or OS among all MBC subtypes. High Ki-67 (p = 0.020) appeared as DFS factor in PMBC, while anti-Her2 targeted therapy (p = 0.047) as the DFS predictors in MMBC.

Conclusion: MMBC manifested similar 5-year survival to PMBC in Chinese woman, suggesting that intra-tumoral heterogeneity might not interfere with MBC short-term prognosis.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8778